We are live on ! Find out more
IBER.WS

Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
IBER.WS

Delisted

IBER.WS was delisted on the 15th of February, 2023.

Back to rankings

30 hedge funds and large institutions have $3.74M invested in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

43% more funds holding

Funds holding: 21 → 30 (+9)

19% more capital invested

Capital invested by funds: $3.14M → $3.74M (+$598K)

Holders
30
Holders Change
+9
Holders Change %
+42.86%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
3
Reduced
2
Closed
–
Calls
$2.22M
Puts
–
Net Calls
+$2.22M
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
SCM
Shaolin Capital Management
Florida
+$112K
2
PC
Periscope Capital
Ontario, Canada
+$70.8K
3
GCL
Glazer Capital LLC
New York
+$55.9K
4
Walleye Capital
Walleye Capital
New York
+$30.9K
5
Walleye Trading
Walleye Trading
New York
+$22.7K

Top Sellers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
-$14.9K
2
Citadel Advisors
Citadel Advisors
Florida
-$4.04K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$1.46M – – –
AA
2
AQR Arbitrage
Connecticut
$365K – – –
DMKJ
3
David M. Knott Jr
$207K +$10.2K +18,000 New
Citadel Advisors
4
Citadel Advisors
Florida
$204K -$4.04K -7,137 -2%
BFM
5
Boothbay Fund Management
New York
$131K +$227 +400 +3%
LA
6
Linden Advisors
New York
$120K – – –
SC
7
Sculptor Capital
New York
$114K – – –
SCC
8
Spring Creek Capital
Kansas
$108K – – –
VI
9
Vestcor Inc
New Brunswick, Canada
$108K – – –
SCM
10
Shaolin Capital Management
Florida
$107K +$112K +198,100 New
MCM
11
Moore Capital Management
New York
$81K – – –
PAMP
12
Polar Asset Management Partners
Ontario, Canada
$80K -$14.9K -26,300 -15%
Nomura Holdings
13
Nomura Holdings
Japan
$78K – – –
CCA
14
Castle Creek Arbitrage
Colorado
$68K – – –
PC
15
Periscope Capital
Ontario, Canada
$67K +$70.8K +124,900 New
Wells Fargo
16
Wells Fargo
California
$66K – – –
PMAM
17
Picton Mahoney Asset Management
Ontario, Canada
$55K – – –
GCL
18
Glazer Capital LLC
New York
$53K +$55.9K +98,705 New
CAC
19
Cowen and Company
New York
$48K +$18.8K +33,091 +60%
ICMH
20
Integrity Capital Management (HK)
Hong Kong
$42K +$43.9K +77,501 New
Walleye Capital
21
Walleye Capital
New York
$29K +$30.9K +54,567 New
BCM
22
Basso Capital Management
Connecticut
$28K – – –
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$22K – – –
Walleye Trading
24
Walleye Trading
New York
$22K +$22.7K +40,000 New
WA
25
Whitebox Advisors
Minnesota
$20K +$21.3K +37,500 New
1
2

IBER.WS Hedge Fund Activity: Q4 2021 in Review

30 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q4 2021, worth a combined $3.74M — up 19% from $3.14M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new IBER.WS positions and 0 closed out — a net gain of 10 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Shaolin Capital Management, opening a new position worth an estimated $112K. The largest seller was Polar Asset Management Partners, cutting an estimated $14.9K.

  • 30 institutional investors held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q4 2021, up from 21 in Q3 2021.
  • Funds reported $3.74M of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q4 2021, up 19% quarter-over-quarter.
  • 10 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q4 2021 and 0 closed out, a net change of +10 holders.
  • The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share buyer in Q4 2021 was Shaolin Capital Management, an estimated $112K added.
  • The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q4 2021 was Polar Asset Management Partners, an estimated $14.9K sold.

Based on aggregated 13F filings for Q4 2021.